INSYS Therapeutics Inc. (INSY)

0.30
0.01 4.52
OTC : Health Technology
Prev Close 0.29
Open 0.28
Day Low/High 0.28 / 0.32
52 Wk Low/High 0.14 / 11.65
Volume 1.09M
Avg Volume 3.70M
Exchange OTC
Shares Outstanding 74.57M
Market Cap 21.71M
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
INSY: Insiders vs. Shorts

INSY: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 01/15/2014 settlement date, and Insys Therapeutics Inc is one of the most shorted stocks of the Russell 3000, based on 4.41 "days to cover" versus the median component at 3.97. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $100,000 In Losses From Investment In Insys Therapeutics, Inc. To Contact Brower Piven Before The February 14, 2014 Lead Plaintiff Deadline

SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $100,000 In Losses From Investment In Insys Therapeutics, Inc. To Contact Brower Piven Before The February 14, 2014 Lead Plaintiff Deadline

Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Arizona on behalf of purchasers of Insys Therapeutics, Inc.

Biotech 2013 by the Numbers: A Blockbuster Year

Biotech 2013 by the Numbers: A Blockbuster Year

The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.

'Fast Money' Recap: Looking for Bargains

'Fast Money' Recap: Looking for Bargains

The trading panel discussed the market pullback and what to buy next.

Insys Therapeutics (INSY) Highlighted As Today's Perilous Reversal Stock

Insys Therapeutics (INSY) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Insys Therapeutics (INSY) as a "perilous reversal" (up big yesterday but down big today) candidate

Insider Trading Alert - MPWR, FOSL, NWBI, MAR And INSY Traded By Insiders

Insider Trading Alert - MPWR, FOSL, NWBI, MAR And INSY Traded By Insiders

Stocks with insider trader activity include MPWR, FOSL, NWBI, MAR and INSY

Insys Therapeutics (INSY) Is Today's Dead Cat Bounce Stock

Insys Therapeutics (INSY) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Insys Therapeutics (INSY) as a "dead cat bounce" (down big yesterday but up big today) candidate

Insider Trading Alert - MPWR, FOSL, NWBI, MAR And INSY Traded By Insiders

Insider Trading Alert - MPWR, FOSL, NWBI, MAR And INSY Traded By Insiders

Stocks with insider trader activity include MPWR, FOSL, NWBI, MAR and INSY

Shareholder Alert -- Girard Gibbs LLP Investigates Potential Securities Claims On Behalf Of Investors Of INSYS Therapeutics, Inc. (INSY)

Shareholder Alert -- Girard Gibbs LLP Investigates Potential Securities Claims On Behalf Of Investors Of INSYS Therapeutics, Inc. (INSY)

Girard Gibbs LLP, a national law firm specializing in securities litigation, is investigating potential claims on behalf of purchasers of INSYS Therapeutics, Inc.

Two Biopharmaceutical Companies Moving Markets on Friday

Two Biopharmaceutical Companies Moving Markets on Friday

Coronado Biosciences (CNDO) and Insys Therapeutics (INSY) were moving markets on Friday.

Heavy Trading On Insys Therapeutics (INSY) Before Market Open

Heavy Trading On Insys Therapeutics (INSY) Before Market Open

Trade-Ideas LLC identified Insys Therapeutics (INSY) as a pre-market mover with heavy volume candidate

Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Investors Of Insys Therapeutics, Inc.

Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Investors Of Insys Therapeutics, Inc.

Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Insys Therapeutics, Inc.

Insider Trading Alert - FLT, HK, PDCO, ACT And INSY Traded By Insiders

Insider Trading Alert - FLT, HK, PDCO, ACT And INSY Traded By Insiders

Stocks with insider trader activity include FLT, HK, PDCO, ACT and INSY

4 Stocks Rising on Unusual Volume

4 Stocks Rising on Unusual Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

Ratings Changes Today

Upgrades: BMRN, CSPI, DLPH, GSB, QGEN, RCKY, RDEN, SCLN, SGOC, VAC, WOOF Downgrades: ATAX, BONA, CMLP, CRME, EGAS, FORR, FULL, KRNY, PCYG, QSII, VHI Initiations: ALEX, CZR, INSY, LGP, MCBK, USMD, WDAY Read on to get TheStreet Quant Ratings' detailed report:

Commit To Buy Insys Therapeutics At $35, Earn 29.7% Annualized Using Options

Commit To Buy Insys Therapeutics At $35, Earn 29.7% Annualized Using Options

Investors eyeing a purchase of Insys Therapeutics Inc shares, but tentative about paying the going market price of $40.37/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2014 put at the $35 strike, which has a bid at the time of this writing of $5.10.

5 Stocks Spiking on Unusual Volume

5 Stocks Spiking on Unusual Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

5 Stocks Poised to Break Out

5 Stocks Poised to Break Out

These stocks look ready to break out and trade higher from current levels.

'Mad Money' Lightning Round: Unhappy With AIG

'Mad Money' Lightning Round: Unhappy With AIG

Cramer says he can finally get behind DryShips but is lukewarm on Wabash National.

'Mad Money' Lightning Round: Facebook Is Under Pressure

'Mad Money' Lightning Round: Facebook Is Under Pressure

Insys Therapeutics has defied gravity, Cramer says, but Deere is not among his favorites.

Jim Cramer's 'Mad Money' Recap: A Gloom and Doom Forecast

Jim Cramer's 'Mad Money' Recap: A Gloom and Doom Forecast

Even Janet Yellen can't buoy the markets for long, Cramer says.

Biotech Stocks Fall Most in Two Years Amidst Debt Ceiling Fears

Biotech Stocks Fall Most in Two Years Amidst Debt Ceiling Fears

Today's selling in the biotech sector will re-invigorate the debate about whether a bubble is about to pop.

Stocks With Earnings Revised Up

Stocks With Earnings Revised Up

This trend is a good indication that business is going well.

Jim Cramer's Top Stock Picks: ACAD CLDX INSY NYX

Jim Cramer's Top Stock Picks: ACAD CLDX INSY NYX

Cramer thinks Acadia Pharmaceuticals, Celldex Therapeutics and Insys Therapeutics are three winning biotechs.

Jim Cramer's 'Mad Money' Recap: 2,000 Shows and Counting

Jim Cramer's 'Mad Money' Recap: 2,000 Shows and Counting

Don't let the current political environment blind you to opportunities, Cramer advises.

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan

Cramer will be watching Washington and a number of stocks.

4 Biotech Stocks Rising on Unusual Volume

4 Biotech Stocks Rising on Unusual Volume

Keep these big-volume biotech stocks on your radar.

Organic IPOs: BioAmber, Insys

Organic IPOs: BioAmber, Insys

From green technology to medicinal marijuana, investors will be surprised at which IPO looks good. Francis Gaskins gives details.